Aurinia Pharmaceuticals (AUPH) EBITDA Margin (2015 - 2026)
Aurinia Pharmaceuticals posted quarterly EBITDA Margin of 43.85% for Q1 2026, up 676.0% year-on-year from 5.65% in Q1 2025, and down 83.97% on a QoQ basis from 273.55% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) has 10 years of EBITDA Margin data on file, last reported at 43.85% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 676.0% year-over-year to 43.85%; the trailing twelve-month figure through Mar 2026 stood at 99.95% (up 8383.0% YoY), and the FY2025 full-year result was 101.48%, up 9900.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 43.85%, down from 273.55% in the prior quarter.
- Across five years, EBITDA Margin topped out at 273.55% in Q4 2025 and bottomed at 177.55% in Q1 2022.
- The 5-year median for EBITDA Margin is 15.53% (2022), against an average of 9.74%.
- The widest annual swing landed in 2022, when EBITDA Margin surged 533372 bps; it then sank 900 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 89.96% in 2022, then jumped by 34 bps to 59.12% in 2023, then surged by 103 bps to 1.95% in 2024, then jumped by 13933 bps to 273.55% in 2025, then plunged by 84 bps to 43.85% in 2026.
- The last three EBITDA Margin figures came in at 43.85% (Q1 2026), 273.55% (Q4 2025), and 43.16% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn | 43.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.85% |
| Dec 31, 2025 | 273.55% |
| Sep 30, 2025 | 43.16% |
| Jun 30, 2025 | 30.62% |
| Mar 31, 2025 | 37.09% |
| Dec 31, 2024 | 1.95% |
| Sep 30, 2024 | 21.87% |
| Jun 30, 2024 | 1.25% |
| Mar 31, 2024 | -21.62% |
| Dec 31, 2023 | -59.12% |
| Sep 30, 2023 | -24.53% |
| Jun 30, 2023 | -27.77% |
| Mar 31, 2023 | -75.95% |
| Dec 31, 2022 | -89.96% |
| Sep 30, 2022 | -15.53% |
| Jun 30, 2022 | -126.81% |
| Mar 31, 2022 | -177.55% |
| Dec 31, 2021 | -142.63% |
| Sep 30, 2021 | -342.65% |
| Jun 30, 2021 | -710.02% |
| Mar 31, 2021 | -5,511.27% |
| Dec 31, 2020 | -16.14% |
| Sep 30, 2020 | -145,275.86% |
| Jun 30, 2020 | -91,531.03% |
| Dec 31, 2019 | -120,141.38% |
| Dec 31, 2018 | -50,320.69% |
| Sep 30, 2015 | -2,926.97% |
| Jun 30, 2015 | -605.79% |